Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy.
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Drug Des Devel Ther. 2021 Mar 10;15:1135-1147. doi: 10.2147/DDDT.S240866. eCollection 2021.
Atopic dermatitis (AD) is a chronic, pruritic, inflammatory skin disease that predominantly affects children. However, it can persist in adulthood and/or start at older ages. Both dysfunction of the epidermal barrier and immune dysregulation are known to play a role in the pathogenesis of AD. In the last years, numerous studies showed that Janus kinase (JAK) enzymes have a key role in AD pathogenesis. Therefore, oral and topical JAK inhibitors are new emerging treatments for AD. We report the data relating to abrocitinib, an oral JAK1 inhibitor. For this purpose, we examined articles already published concerning, in particular, concluded clinical trials. Furthermore, we also report the design of current ongoing clinical trials. The search was carried out considering the main search engines relating to medical literature and clinical trials. From all the data we collected, abrocitinib proved to be an effective drug in significantly reducing the severity of moderate-to-severe AD when compared to placebo. Furthermore, the efficacy was similar to other well-established treatment for AD, such as dupilumab. Adverse events were generally mild; indeed, the drug was definitively suspended only in few patients.
特应性皮炎（AD）是一种慢性、瘙痒性、炎症性皮肤病，主要影响儿童。然而，它也可以持续到成年期和/或在老年时发作。表皮屏障功能障碍和免疫失调都被认为在 AD 的发病机制中起作用。近年来，许多研究表明，Janus 激酶（JAK）酶在 AD 的发病机制中起关键作用。因此，口服和局部 JAK 抑制剂是 AD 的新出现的治疗方法。我们报告了有关 abrocitinib 的数据，这是一种口服 JAK1 抑制剂。为此，我们研究了已经发表的有关特别是已完成的临床试验的文章。此外，我们还报告了当前正在进行的临床试验的设计。搜索考虑了与医学文献和临床试验相关的主要搜索引擎。从我们收集的所有数据来看，与安慰剂相比，abrocitinib 被证明在显著减轻中重度 AD 的严重程度方面是一种有效的药物。此外，其疗效与 AD 的其他成熟治疗方法（如 dupilumab）相似。不良反应通常较轻；事实上，该药物仅在少数患者中被停用。
